Vera Therapeutics, Inc. (NASDAQ:VERA) Stake Lessened by Decheng Capital LLC

Key Points

• Decheng Capital LLC reduced its stock position in Vera Therapeutics by 91.0%, owning only 4,495 shares at the end of the first quarter, making it a negligible part of their portfolio.
• Several institutional investors have recently increased their stakes in Vera Therapeutics, with holdings now comprising 99.21% of the company's stock.
• Vera Therapeutics reported a quarterly loss of ($0.81) per share, which was below analysts' expectations, and they anticipate an annual EPS of -2.89 for the current year.

Decheng Capital LLC trimmed its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 91.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,495 shares of the company's stock after selling 45,272 shares during the period. Vera Therapeutics comprises about 0.0% of Decheng Capital LLC's holdings, making the stock its 26th biggest position. Decheng Capital LLC's holdings in Vera Therapeutics were worth $108,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of VERA. Avoro Capital Advisors LLC raised its position in shares of Vera Therapeutics by 30.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock worth $237,247,000 after purchasing an additional 1,300,410 shares during the last quarter. Vestal Point Capital LP purchased a new stake in Vera Therapeutics in the 4th quarter worth approximately $45,462,000. Lord Abbett & CO. LLC grew its stake in Vera Therapeutics by 170.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company's stock worth $48,788,000 after acquiring an additional 727,656 shares during the period. Federated Hermes Inc. grew its stake in Vera Therapeutics by 162.2% in the 4th quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company's stock worth $45,926,000 after acquiring an additional 671,881 shares during the period. Finally, Integral Health Asset Management LLC grew its stake in Vera Therapeutics by 130.0% in the 4th quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company's stock worth $48,634,000 after acquiring an additional 650,000 shares during the period. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Stock Up 0.8%

Shares of Vera Therapeutics stock traded up $0.16 during trading on Friday, reaching $20.95. The company had a trading volume of 1,000,400 shares, compared to its average volume of 859,998. The company has a debt-to-equity ratio of 0.10, a quick ratio of 27.68 and a current ratio of 27.68. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The firm's fifty day moving average is $22.90 and its 200-day moving average is $25.55. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -6.98 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter last year, the company earned ($0.56) EPS. On average, analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Cantor Fitzgerald lowered their price objective on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $85.00 price target (up from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. Scotiabank reaffirmed an "outperform" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Wedbush cut their price objective on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Finally, Guggenheim reiterated a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $65.00.

Insider Buying and Selling at Vera Therapeutics

In other news, Director Patrick G. Enright bought 40,607 shares of the firm's stock in a transaction on Tuesday, June 24th. The stock was purchased at an average price of $22.35 per share, for a total transaction of $907,566.45. Following the transaction, the director owned 3,596,593 shares in the company, valued at approximately $80,383,853.55. This trade represents a 1.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 16.30% of the stock is currently owned by corporate insiders.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.